Arvee Laboratories (India) Q4 FY26 Results: PAT Rs 0.50 Cr, Revenue Rs 9.00 Crore

Arvee Laboratories (India) Q4 FY26 results were declared on May 18, 2026, at the board of directors meeting. Arvee Laboratories (India) reported PAT of Rs 0.50 crore for the quarter ended March 31, 2026, Q4 FY26 (results declared May 18, 2026), on revenue of Rs 9.00 crore for the quarter ended March 31, 2026. Arvee Laboratories (India) is a specialty chemicals including polymer modifiers and drug intermediates business. This article covers the complete Arvee Laboratories (India) Q4 FY26 financial highlights, key performance factors, and FY27 outlook.

Click Here – Get Free Investment Predictions

Arvee Laboratories (India) Q4 FY26 Financial Highlights

Note: 9M FY26 PAT Rs 2.01 crore on revenue Rs 21.24 crore. Q3 FY26 revenue Rs 9.92 crore. Q4 FY26 derived ~Rs 9 crore revenue, ~Rs 0.5 crore PAT. Ahmedabad-based DSIR-certified specialty chemicals manufacturer.

Arvee Laboratories (India) Q4 FY26 Performance Analysis

Arvee Laboratories (India) Q4 FY26 reflects operational performance during the January to March 2026 period. Arvee Laboratories (India) operates in the specialty chemicals including polymer modifiers and drug intermediates space, a sector supported by India’s sustained domestic demand and strong GDP growth trajectory. The Q4 FY26 results demonstrate business resilience amid a competitive market.

Investors monitoring Arvee Laboratories (India) Q4 FY26 will focus on FY27 revenue guidance, cost rationalisation, and strategic execution.

Check the Univest Screener for live data

Key Business Factors for Arvee Laboratories (India) Q4 FY26

Revenue and Operational Execution

Revenue of Rs 9.00 crore in Arvee Laboratories (India) Q4 FY26 for the quarter ended March 31, 2026 reflects the company’s specialty chemicals including polymer modifiers and drug intermediates business trajectory. India’s macroeconomic environment, with GDP growth above 6.5% and strong consumption demand, provides a constructive backdrop for the sector.

Profitability and FY27 Outlook

The Arvee Laboratories (India) Q4 FY26 PAT of Rs 0.50 crore Q4 FY26 (results declared May 18, 2026). Management commentary on FY27 priorities, capital allocation, and order pipeline will be key watchpoints for investors. The company’s ability to sustain profitability and grow market share in FY27 will determine investor sentiment.

Sector Tailwinds

The specialty chemicals including polymer modifiers and drug intermediates sector benefits from India’s structural growth drivers, including government infrastructure investment, rising consumption, and digital adoption. These factors support the medium-term revenue outlook for Arvee Laboratories (India) beyond Q4 FY26.

Download the Univest iOS App or Univest Android App to receive SEBI-registered analyst research on Arvee Laboratories (India) and similar companies.

India Economic Context for Arvee Laboratories (India)

The January to March 2026 quarter was characterised by steady domestic consumption, fiscal year-end procurement cycles, and government infrastructure push. India’s GDP growth rate remained above 6.5% for the period, providing a supportive backdrop for companies across sectors. The Reserve Bank of India maintained an accommodative policy stance, while rural demand and urban consumption both contributed to broad-based economic activity. For companies like Arvee Laboratories (India), this environment provided a stable demand base even as individual quarter results reflect company-specific operational factors and execution quality.

The Arvee Laboratories (India) Q4 FY26 results also come at a time when India is emerging as a preferred destination for global supply chain realignment, benefiting industrial and manufacturing sectors. Investors tracking the financial results of micro-cap and small-cap companies should contextualise quarterly performance within the broader FY27 strategic outlook and management guidance provided alongside the results.

Frequently Asked Questions on Arvee Laboratories (India) Q4 FY26

What is Arvee Laboratories (India) Q4 FY26 PAT?

Ans. The firm PAT was PAT of Rs 0.50 crore Q4 FY26 (results declared May 18, 2026). Results were declared on May 18, 2026. Always verify from NSE/BSE filings before making any investment decision.

What is Arvee Laboratories (India) Q4 FY26 revenue?

Ans. Arvee revenue from operations was Rs 9.00 crore for the quarter ended March 31, 2026. Track live financials on the Univest Screener.

When were Arvee Laboratories (India) Q4 FY26 results announced?

Ans. The company results were announced on May 18, 2026, at the board of directors meeting that approved audited Q4 and FY26 financial statements.

Is Arvee Laboratories (India) a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, valuation, risk tolerance, and investment horizon. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.